http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007143434-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2006-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007143434-A |
| titleOfInvention | 4-ANILINO-3-CHINOLINE CARBONITRILS SUITABLE FOR TREATING CANCER DISEASES |
| abstract | 1. A method of preventing, treating or suppressing cancer, comprising administering a therapeutically effective amount of a compound of formula (I):! ! or a pharmaceutically acceptable salt thereof. ! 2. The method according to claim 1, characterized in that said cancer, which is prevented, treated or suppressed, is pancreatic cancer. ! 3. The method according to claim 1, characterized in that said cancer, which is prevented, treated or suppressed, is a cancer of the lymphatic system. ! 4. The method according to claim 1, characterized in that said cancer, which is prevented, treated or inhibited, is prostate cancer. ! 5. The method according to claim 1, characterized in that said cancer, which is prevented, treated or suppressed, is a cancer of the neck and head. ! 6. The method according to claim 1, characterized in that said cancer, which is prevented, treated or suppressed, is melanoma. ! 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I):! ! or its pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier. ! 8. The method according to claim 1, characterized in that said compound is administered alone or in combination with one or more other compounds used to treat cancer. ! 9. The method of claim 8, wherein said other compounds are selected from the group consisting of imatinibmesylate, hydroxyurea, IFN-ά, cytotoxic agents, genfitanib, gemcitabine, avastin and wortmannin, or pharmaceutically |
| priorityDate | 2005-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.